Who owns Autolus Therapeutics plc (AUTL)? Elite investor 13F holders
2 tracked elite investors reported holding Autolus Therapeutics plc as of 2026-06-30, including Renaissance Technologies LLC, Alphabet. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | AUTOLUS THERAPEUTICS PLC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 3175520.00 USD | 1984700.000000 | Shares | reduce | Original filing |
| Alphabet | AUTOLUS THERAPEUTICS PLC | SHARE | 2026-06-30 | 2026-08-07 00:00:00 | 1117219.00 USD | 698262.000000 | Shares | hold | Original filing |
| Tudor Investment | AUTOLUS THERAPEUTICS PLC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.